Ph- ALL: immunotherapy in upfront treatment.

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Relapsed or refractory (R/R) B-cell precursor acute lymphoblastic leukemia (ALL) has limited treatment options.
• Current standard therapies include antibody-based and cell-based immunotherapies like bispecific T-cell engagers (BiTEs), antibody-drug conjugates, and chimeric antigen receptor (CAR) T cells.
• CD20-targeting monoclonal antibodies and the CD19-targeting BiTE blinatumomab are established in frontline therapy for specific ALL patient groups.

Purpose of the Study:

• To evaluate the efficacy of antibody-based immunotherapies in the upfront treatment of ALL.
• To explore the potential of these novel agents in older adult patients with poor prognoses.
• To assess the role of immunotherapies in reducing or replacing conventional chemotherapy.

Main Methods:

• Prospective study of antibody-based immunotherapies in the upfront setting.
• Integration of immunotherapeutic agents, potentially reducing or replacing conventional chemotherapy.
• Focus on patients with B-cell precursor ALL, including older adults and those with R/R disease.

Main Results:

• High response rates and improved survival outcomes observed in patients with R/R ALL treated with antibody-based immunotherapies.
• Blinatumomab demonstrated a survival benefit in patients with measurable disease (MRD)-negative ALL.
• Promising outcomes reported when conventional chemotherapy is reduced or replaced by immunotherapeutic agents.

Conclusions:

• Antibody-based immunotherapies are demonstrating significant efficacy in B-cell precursor ALL.
• These novel therapies offer a promising alternative or supplement to conventional chemotherapy, particularly for older adults.
• Further evaluation is ongoing to establish new treatment standards incorporating these immunotherapeutic approaches.